An emerging class of orexin-based drugs are on the cusp of disrupting care for sleep disorders — and potentially much more.

The Food and Drug Administration (FDA) recently expanded approval for Spravato, an antidepressant nasal spray used to treat depression. Parkside Psychiatric Hospital has a Spravato outpatient clinic ...

Spravato has been approved since 2019 for TRD, with its label extended the following year as a rescue therapy for adults with major depressive disorder (MDD) who were at risk of self-harm or suicide.

The FDA has approved Janssen’s antidepressant nasal spray Spravato, making it the first new type of depression treatment to hit the market in 30 years – although its use will be restricted to ...

Q4 2024 Earnings Call Transcript February 7, 2025 Operator: Ladies and gentlemen, thank you for standing by. Welcome to ...

Vanessa Kanu Kanu; Executive Vice President and Chief Financial Officer; Aptargroup Inc Ladies and gentlemen, thank you for standing by. Welcome to Aptar 2024 fourth quarter and annual results ...

Viking Therapeutics Announces Initiation of Phase 2 VENTURE-Oral Dosing Trial of VK2735 Tablet Formulation in Patients with Obesity Company announced the initiation of a 13-week study to evaluate ...

Dosing a statin (rosuvastatin) every other day (EOD) may provide significant lipoprotein changes while avoiding common adverse effects in this statin-intolerant population. Objective: To determine ...

A roundup of the most newsworthy healthcare press releases from PR Newswire, including Zimmer Biomet's acquisition of Paragon 28, Icy Hot's partnership with Unrivaled and three major health news ...

US FDA OKs monthly maintenance dosing for Eisai/Biogen's ... expanded approval for Johnson & Johnson's nasal spray, Spravato, to allow it to be used as a standalone treatment for patients with ...